Dec 17, 2020
* * *
Managing vitiligo can be difficult for both patients and physicians. In this episode, guest host Seemal R. Desai, MD, (@SeemalRDesaiMD) talks to Pearl E. Grimes, MD, about how to better classify vitiligo disease status and parameters that impact treatment choice. “There are some aspects of classification that are really key from a therapeutic as well as a prognostic perspective. The things that I look at on a day-to-day basis when I workup any new patient [include asking], what type of vitiligo do you have? Is it nonsegmental or is it segmental? Is the patient stable or are they progressive? And then I look at the severity of disease,” Dr. Grimes explains. They discuss the importance of stabilizing vitiligo, particularly on the face, and highlight the psychosocial impact of the disease. Dr. Grimes also highlights the role of supplements and antioxidants such as vitamin D in vitiligo treatment.
* * *
Hosts: Seemal R. Desai, MD (Innovative Dermatology, Dallas, and the University of Texas Southwestern Medical Center, Dallas)
Guests: Pearl E. Grimes, MD (Vitiligo & Pigmentation Institute of Southern California, Los Angeles)
Disclosures: Dr. Desai reports no conflict of interest. Dr. Grimes has conducted clinical research and/or served as a consultant for Clinuvel Pharmaceuticals, Dermaforce, Johnson & Johnson, Incyte, LaserOptek, L’Oréal, Pfizer, Procter & Gamble, and VT Technologies.
Show notes by: Alicia Sonners, Melissa Sears
* * *
You can find more of our podcasts at http://www.mdedge.com/podcasts
Email the show: email@example.com
Interact with us on Twitter: @MDedgeDerm